Pfizer Inc. Price to Book Ratio 2010-2024 | PFE

Historical price to book ratio values for Pfizer Inc. (PFE) over the last 10 years. The current price to book ratio for Pfizer Inc. as of February 24, 2025 is 1.61.

Please refer to the Stock Price Adjustment Guide for more information on our historical prices.

Pfizer Inc. Price/Book Ratio Historical Data
Date Stock Price Book Value per Share Price to Book Ratio
2025-02-21 26.30 1.61
2024-09-30 28.49 $16.34 1.74
2024-06-30 27.18 $15.52 1.75
2024-03-31 26.56 $16.33 1.63
2023-12-31 27.14 $15.81 1.72
2023-09-30 30.84 $17.22 1.79
2023-06-30 33.72 $17.59 1.92
2023-03-31 37.10 $17.93 2.07
2022-12-31 46.17 $17.08 2.70
2022-09-30 39.09 $16.55 2.36
2022-06-30 46.47 $15.64 2.97
2022-03-31 45.53 $14.79 3.08
2021-12-31 51.54 $13.78 3.74
2021-09-30 37.21 $13.54 2.75
2021-06-30 33.57 $12.56 2.67
2021-03-31 30.76 $12.31 2.50
2020-12-31 30.91 $11.40 2.71
2020-09-30 28.92 $11.79 2.45
2020-06-30 25.52 $11.62 2.20
2020-03-31 25.21 $11.77 2.14
2019-12-31 29.96 $11.46 2.61
2019-09-30 27.21 $11.82 2.30
2019-06-30 32.50 $10.77 3.02
2019-03-31 31.58 $10.65 2.97
2018-12-31 32.19 $11.15 2.89
2018-09-30 32.25 $12.40 2.60
2018-06-30 26.32 $11.96 2.20
2018-03-31 25.50 $12.06 2.11
2017-12-31 25.79 $11.98 2.15
2017-09-30 25.19 $10.25 2.46
2017-06-30 23.47 $9.87 2.38
2017-03-31 23.67 $9.84 2.40
2016-12-31 22.25 $9.86 2.26
2016-09-30 22.97 $10.48 2.19
2016-06-30 23.68 $10.40 2.28
2016-03-31 19.76 $10.44 1.89
2015-12-31 21.30 $10.53 2.02
2015-09-30 20.56 $10.87 1.89
2015-06-30 21.78 $10.89 2.00
2015-03-31 22.41 $10.98 2.04
2014-12-31 19.89 $11.38 1.75
2014-09-30 18.72 $12.43 1.51
2014-06-30 18.62 $12.14 1.53
2014-03-31 19.97 $12.24 1.63
2013-12-31 18.89 $11.97 1.58
2013-09-30 17.58 $12.09 1.45
2013-06-30 17.00 $11.93 1.42
2013-03-31 17.37 $11.68 1.49
2012-12-31 14.96 $11.23 1.33
2012-09-30 14.69 $11.15 1.32
2012-06-30 13.48 $10.71 1.26
2012-03-31 13.14 $11.17 1.18
2011-12-31 12.43 $10.91 1.14
2011-09-30 10.05 $11.78 0.85
2011-06-30 11.59 $11.40 1.02
2011-03-31 11.31 $11.46 0.99
2010-12-31 9.65 $11.02 0.88
2010-09-30 9.37 $10.99 0.85
2010-06-30 7.69 $10.81 0.71
2010-03-31 9.16 $11.17 0.82
2009-12-31 9.62 $11.21 0.86
2009-09-30 8.67 $8.21 1.06
2009-06-30 7.78 $9.37 0.83
2009-03-31 6.98 $8.96 0.78
Sector Industry Market Cap Revenue
Medical Large Cap Pharma $149.042B $63.627B
Pfizer Inc. is a research-based, global biopharmaceutical company. The company boasts a sustainable pipeline with multiple late-stage programs that can drive growth. Pfizer markets a wide range of drugs and vaccines. Its business comprises six business units - Oncology, Inflammation & Immunology, Rare Disease, Hospital, Vaccines and Internal Medicine. Pfizer spinned-off its Upjohn unit, its off-patent branded and generic established medicines business, and combined it with generic drugmaker Mylan to create a new generic pharmaceutical company called Viatris. The Consumer Healthcare (CHC) segment, an over-the-counter (OTC) medicines business, was merged with Glaxo's unit to form a new joint venture.?The Consumer Healthcare joint venture with Glaxo and the merger of Upjohn unit with Mylan has made Pfizer a smaller company with a diversified portfolio of innovative drugs and vaccines.
Stock Name Country Market Cap PE Ratio
Eli Lilly and Company (LLY) US $828.397B 67.21
Novo Nordisk A/S (NVO) DK $395.262B 26.77
Johnson & Johnson (JNJ) US $390.756B 16.25
AbbVie Inc. (ABBV) US $356.743B 19.97
Roche Holding AG (RHHBY) CH $264.174B 0.00
Merck & Co., Inc. (MRK) US $226.402B 11.72
Novartis AG (NVS) CH $223.511B 14.00
Sanofi (SNY) $138.211B 13.09
Bayer Aktiengesellschaft (BAYRY) DE $22.635B 3.62
Innoviva, Inc. (INVA) US $1.132B 9.42